Welcome to our dedicated page for Reviva Pharmaceutcls Hldgs news (Ticker: RVPH), a resource for investors and traders seeking the latest updates and insights on Reviva Pharmaceutcls Hldgs stock.
Reviva Pharmaceuticals Holdings, Inc. develops therapies for central nervous system, inflammatory and cardiometabolic diseases as a late-stage biopharmaceutical company. News about RVPH centers on brilaroxazine (RP5063), a clinical-stage program for schizophrenia and other neuropsychiatric indications, as well as RP1208, with both drug candidates described as new chemical entities discovered in-house.
Recurring updates include clinical and regulatory communications, intellectual-property strategy, peer-reviewed data publications, corporate presentations, annual and interim financial results, and equity or warrant financings used to support research and development and working capital.
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, has announced a proposed public offering of common stock and warrants. The offering will include shares of common stock (or equivalents) and warrants to purchase common stock, with A.G.P./Alliance Global Partners serving as the sole placement agent.
The proceeds will be used to fund research and development activities and for working capital purposes. The securities will be offered through an effective shelf registration statement on Form S-3. The completion of the offering is subject to market conditions, with no guaranteed size or terms.
Reviva Pharmaceuticals (NASDAQ: RVPH) has reported significant progress in its brilaroxazine development program for schizophrenia treatment, alongside Q2 2025 financial results. The company successfully completed its Phase 3 RECOVER open-label extension (OLE) 1-year study, demonstrating sustained efficacy across all symptom domains and a well-tolerated safety profile.
Key clinical achievements include robust broad-spectrum efficacy with improvements in PANSS total score (-18.1), positive symptoms (-5.0), and negative symptoms (-4.4). The company plans to meet with the FDA in Q4 2025 to discuss the path to approval, with a potential NDA submission targeted for Q2 2026.
Financially, Reviva reported a net loss of $6.1 million ($0.12 per share) for Q2 2025, compared to $7.9 million in Q2 2024. The company's cash position stands at $10.4 million, bolstered by a recent $10.0 million public equity offering.
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, has announced a $10 million public offering. The offering includes 20 million shares of common stock (or equivalents) at $0.50 per share, along with Series C and D warrants to purchase up to 20 million additional shares each.
The Series C warrants have a 5-year expiration while Series D warrants expire in 12 months, both with an exercise price of $0.50 per share. The offering is expected to close around June 27, 2025. Proceeds will fund R&D activities and general corporate purposes, with A.G.P./Alliance Global Partners acting as sole placement agent.
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, has announced a proposed public offering of common stock and warrants. The offering will be managed by A.G.P./Alliance Global Partners as the sole placement agent.
The company plans to use the proceeds to fund research and development activities and for working capital purposes. The securities will be offered under an effective shelf registration statement filed with the SEC. The final size, terms, and completion of the offering are subject to market conditions.
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for CNS, inflammatory and cardiometabolic diseases, has announced its participation in two upcoming investor conferences in May 2025.
CEO Laxminarayan Bhat will attend the Benchmark Healthcare House Call Virtual Investor Conference for a fireside chat and 1x1 meetings on May 29 at 11:15 a.m. ET, and the Lytham Partners Spring 2025 Investor Conference for a company presentation and 1x1 meetings on the same day at 2:00 p.m. ET. Both events will be held virtually.
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases, has announced its participation in the upcoming A.G.P. Healthcare Company Showcase. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will engage in a fireside chat during the virtual event scheduled for May 21, 2025, at 2:00 p.m. EST.
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company, has announced its participation in the upcoming Citizens Life Sciences Conference in New York. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will deliver a corporate update through a fireside chat format.
The presentation is scheduled for Thursday, May 8, 2025, at 10:30 a.m. ET. Reviva focuses on developing therapies for:
- Central nervous system (CNS) diseases
- Inflammatory conditions
- Cardiometabolic diseases
The company aims to address unmet medical needs in these therapeutic areas. A webcast link has been provided for interested parties to access the presentation.